Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin vs Catecholamines in Hepatic Patients with Septic Shock
NCT03608514Phase 3Unknown
- Sponsor
- National Hepatology and Tropical Medicine Research Institute
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of terlipressin in septic shock (2 arms), sponsored by National Hepatology and Tropical Medicine Research Institute. Primary endpoints: Mean Arterial Pressure at 7 days, Mortality at 28 days and 1 more. Status: unknown.
02
Drugs
terlipressin
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT03608514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608514.